KEI’s opening statement at WIPO’s 2017 General Assembly focuses on role of Chief Economist

This was delivered the afternoon on October 3, 2017.

Opening statement of Knowledge Ecology International – WIPO General Assembly 2017

Thank you, Mr. Vice President.

KEI notes the controversies around the world regarding the costs and benefits of intellectual property policies, including in particular extended terms of copyright protection in some countries, access to copyrighted works out of commerce and in teaching and research, and the role of patents in both promoting and discouraging innovation, and creating barriers to access medicine.

Continue Reading

SEARO RC70: India calls on WHO to take the lead in negotiations of the R&D treaty (General Programme of Work debate)

As noted in an earlier piece, on 25 August 2017 the WHO published a draft concept note to provide a road map to “underpin WHO’s General Programme of of Work from 2019-2023… and serve as the strategic basis for resource mobilization” for the Organization (WHO draft concept note on strategic priorities for 2019-2023 charts a new vision for the organization, 29 August 2017, KEI). Continue Reading

2017: Nanobernetics proposed exclusive license for NIH patents on Apparatus for Microarray Binding Sensors

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) The attached file (copy here) is the KEI questions and initial comments on the Prospective Grant of an Exclusive Patent License: Apparatus for Microarray Binding Sensors Having… Continue Reading

NIH response to KEI request for NIH policy on on the licensing of federally-funded CRISPR patented inventions.

On June 6, 2017, KEI wrote to Dr. Thomas Price, Secretary of Health and Human Services (HHS), and Dr. Francis S. Collins, Director of the National Institutes of Health (NIH) requesting the HHS develop a policy on the licensing of federally-funded CRISPR patented inventions. A copy of our letter is available here: /node/2801.

Continue Reading

KEI and Médecins Sans Frontières propose contractual terms to protect access and affordability of Zika vaccine

25 July 2017
FOR IMMEDIATE RELEASE
CONTACT: Kim Treanor, kim.treanor@keionline.org or +1 (202) 332-2670

Washington, 25 July 2017 – Knowledge Ecology International (KEI) and Médecins Sans Frontières (MSF) have sent a letter today to the Command Judge Advocate of the U.S. Army Medical Research and Materiel Command (USAMRMC), recommending two specific contractual terms for the proposed license of the US Army’s Zika vaccine technology to Sanofi Pasteur.

Continue Reading

House Appropriations rejects Kaptur amendment (allow competition for gov funded drugs if prices higher than reference countries)

On 19 July 2017, Rep. Marcy Kaptur (D-OH) introduced an amendment at the markup in the U.S. House Appropriations Committee of the FY2018 State and Foreign Operations, Labor, Health and Human Services Appropriations bill that would direct the Department of Health and Human Services to use its authority to break patent monopolies for government-funded inventions priced higher in the U.S. than seven other high-income countries.

Continue Reading

Senate Armed Services Committee directive on use of Bayh-Dole rights for DoD funded drugs

The report of the Senate Armed Services Committee on the National Defense Authorization Act of 2018, S. 1519, published July 10, 2017, includes a directive that links exclusive patent rights to the prices of drugs, vaccines and other medical technologies that are based upon DoD-funded inventions.

The text of the directive, approved unanimously by the full Senate Armed Services Committee, is as follows:

Continue Reading

SCP26 – Agreement reached on future work reached at WIPO Standing Committee on the Law of Patents (6 July 2017)

On Thursday afternoon, 6 July 2017, the 26th session of the WIPO Standing Committee on the Law of Patents (SCP), chaired by Ms. Bucura Ionescu (Romania) reached agreement on future work on the following issues: i) Exceptions and Limitations to Patent Rights, ii) Quality of Patents, including Opposition Systems, iii) Patents and Health, iv) Confidentiality of Communications between Clients and Their Patent Advisors and v) Transfer of Technology. Continue Reading